Wednesday, July 8, 2026

Patent intelligence · US

US 10106500

Selective androgen receptor modulators (SARMs) and uses thereof

granted A61KA61K31/401A61K31/402A61K31/5383
Status granted
Linked drugs 1
Pipeline programs 6
Years to expiry 12
Applicant portfolio 133
Patent details — US 10106500
Jurisdiction
US
Status
granted
Grant date
Oct 23, 2018
Expiration
Oct 18, 2038
Claims
15
CPC classes
A61K, A61K31/401, A61K31/402, A61K31/5383
View on Google Patents ↗

Quick answer

US 10106500 (Selective androgen receptor modulators (SARMs) and uses thereof) is held by Ligand Pharmaceuticals Incorporated. Status: granted. Granted Oct 23, 2018. Expires Oct 18, 2038 (12 years remaining) — relevant for patent-cliff and LOE planning.

Key facts

Grant date
Expiration
Claims
15
CPC classes
A61K, A61K31/401, A61K31/402, A61K31/5383, A61K45/06, A61P

More from Ligand Pharmaceuticals Incorporated

Related pharmaceutical patents in our USPTO index.

  1. US 12403087

    Topical antiviral compositions, delivery systems, and methods of using the same

    Ligand Pharmaceuticals Incorporated · Expires Aug 28, 2045

    granted
  2. US 12319651

    Crystalline forms and methods of producing crystalline forms of a compound

    Ligand Pharmaceuticals Incorporated · Expires May 29, 2045

    granted
  3. US 12246014

    Azetidine derivatives

    Ligand UK Development Limited · Expires Mar 6, 2045

    granted
  4. US 12208071

    Glucagon receptor antagonists

    Ligand Pharmaceuticals Incorporated · Expires Jan 23, 2045

    granted
  5. US 12123012

    Methods and compositions for nucleic acid and protein payload delivery

    LIGANDAL, INC. · Expires Oct 17, 2044

    granted
  6. US 11970482

    Acetal compounds and therapeutic uses thereof

    Ligand Pharmaceuticals Incorporated · Expires Apr 25, 2044

    granted
  7. US 11952364

    TRK inhibitors useful as anticancer drugs

    TYLIGAND BIOSCIENCE (SHANGHAI) LIMITED · Expires Apr 4, 2044

    granted
  8. US 11773110

    Heterocycle amines and uses thereof

    Ligand Pharmaceuticals Incorporated · Expires Sep 28, 2043

    granted

Frequently asked questions

What is US patent 10106500?

US 10106500 (Selective androgen receptor modulators (SARMs) and uses thereof) is held by Ligand Pharmaceuticals Incorporated. Status: granted. Granted Oct 23, 2018. Expires Oct 18, 2038 (12 years remaining) — relevant for patent-cliff and LOE planning.

Who owns US 10106500?

Ligand Pharmaceuticals Incorporated is listed as the applicant in USPTO PatentsView records indexed by NovaPharmaNews. We track 133 pharmaceutical patents for this assignee.

When does US 10106500 expire?

Our index shows an expiration date of Oct 18, 2038 (12 years from today). Confirm material dates against USPTO, FDA Orange Book, or qualified counsel before contractual decisions.